Krystal Biotech Inc (KRYS)

$310.31 -2.57 (-0.82%)
Market Cap 9.22B
Revenue (ttm) 389.13M
Net Income (ttm) 204.83M
EPS (ttm) N/A
PE Ratio 40.87
Forward PE 38.33
Profit Margin 52.64%
Debt to Equity Ratio 0.00
Volume 316,200
Avg Vol 288,052
Day's Range N/A - N/A
Shares Out 29.48M
Stochastic %K 92%
Beta 0.50
Analysts Strong Sell
Price Target $326.10

Company Profile

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical tri...

Industry: Biotechnology
Sector: Healthcare
Phone: 412 586 5830
Address:
2100 Wharton Street, Suite 701, Pittsburgh, United States
CapitalMonk
CapitalMonk May. 13 at 4:25 AM
$KRYS Price: $310.31 (-0.82%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±1.00% RSI: 70.1 | Momentum: Strong Momentum Volume: +3.1% vs avg Volatility: 2.58% Support: $251.97 | Resistance: $315.17 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
MorganHoratio
MorganHoratio May. 11 at 9:32 PM
Today, all of these stocks hit all-time highs at some point. Arrow Electronics $ARW Powell Industries $POWL Synnex $SNX Krystal Biotech $KRYS Enersys $ENS Today’s ATH list is a perfect showcase of a "Multi-Sector Breakout" across AI infra, Life Sciences, and Supply Chain! 🚀 As of May 11, 2026, $POWL hitting $328 reaffirms its dominance in power distribution. $ARW crossing $202 and $ENS breaking $236 highlight the massive recovery in AI hardware distribution and energy storage. Notably, $KRYS tapping $315 marks a pivotal re-rating for the biotech sector. The takeaway: 2026’s wealth effect is flowing beyond GPUs into "Power, Distribution, and Deep-Tech Bio." Which of these "non-GPU" leaders do you think has the most room to run? Let’s discuss your 2026 strategy below!
0 · Reply
ZManicItalian
ZManicItalian May. 11 at 2:02 PM
$KRYS 🍻🐂
0 · Reply
Doozio
Doozio May. 9 at 12:57 AM
$KRYS ONTO 🐒🍌🧠⏰♾️
0 · Reply
trichomy
trichomy May. 7 at 1:43 PM
$INMB $INMB $KRYS $MESO $NVAX $MRNA There is NO reason why InmuneBio is less than $ 3 right now It is trading at 1.5 right now . Fire sale!!
0 · Reply
trichomy
trichomy May. 6 at 4:40 PM
$INMB $INMB $ABEO $KRYS $MESO $IBRX We are in the eye of the storm . Volume already way up. This is the calm before tomorrow Booyah! Wake up people! 🔥 🔥 INMB 🔥 🔥
2 · Reply
Synaptric
Synaptric May. 6 at 1:35 PM
Narrow-tech-only-market angst? Check out 52-week highs in Healthcare $ARWR $CYTK $JAZZ $BTSG $KRYS
0 · Reply
trichomy
trichomy May. 5 at 9:38 PM
$INMB $INMB expands collab with Anthony Nolan charity for umbilical cord tissue supply to advance CORDStrom hucMSC platform — targeting RDEB (CORDStrom-col7a), solid tumors (TRAIL), OA & more. Prepping for commercial approval! Strong supply deal + regulatory momentum in hot cell/gene therapy & rare disease space. $ABEO $KRYS $MESO $IBRX #biotech #celltherapy #RDEB https://www.stocktitan.net/news/INMB/i-nmune-bio-and-anthony-nolan-announce-strategic-expansion-of-cord-r715r3sueyi2.html
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 5 at 2:26 PM
$KRYS RSI: 65.22, MACD: 4.7468 Vol: 8.86, MA20: 270.13, MA50: 262.71 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
VAK7
VAK7 May. 5 at 3:36 AM
$HOOD $KRYS $NBIS $RCUS $TGTX That was a very nice summary. And picks. And set me up for 75% 1 yeah performance since 5/4/25. TGTX and HOOD are lagging from this cohort of 5. But not for long. Imho TGTX will be over $45 this year; and HOOD will be in triple digits, no doubt about it. I could have done better, but, to my defense, MW should have sold TGTX before summer 2025; I told myself that if he does not do that, or buy out EU rights, i will reduce my TGTX position before 2 year term to buyback EU rights lapses. And I did not. Price you pay for your own indecisiveness.
0 · Reply
Latest News on KRYS
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

May 7, 2026, 8:00 AM EDT - 6 days ago

Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

Krystal Biotech price target raised to $300 from $295 at Evercore ISI

2026-05-05T12:35:28.000Z - 7 days ago

Krystal Biotech price target raised to $300 from $295 at Evercore ISI

Krystal Biotech price target raised to $378 from $371 at Citi

2026-05-05T10:40:32.000Z - 8 days ago

Krystal Biotech price target raised to $378 from $371 at Citi

Krystal Biotech price target lowered to $311 from $338 at Clear Street

2026-05-04T16:07:40.000Z - 8 days ago

Krystal Biotech price target lowered to $311 from $338 at Clear Street

Krystal Biotech Earnings Call Transcript: Q1 2026

May 4, 2026, 8:30 AM EDT - 9 days ago

Krystal Biotech Earnings Call Transcript: Q1 2026

Krystal Biotech sees FY26 R&D and SG&A expense $175M-$195M

2026-05-04T11:15:40.000Z - 9 days ago

Krystal Biotech sees FY26 R&D and SG&A expense $175M-$195M

Krystal Biotech reports Q1 EPS $1.83, consensus $1.42

2026-05-04T11:06:39.000Z - 9 days ago

Krystal Biotech reports Q1 EPS $1.83, consensus $1.42

Krystal Biotech Announces First Quarter 2026 Financial and Operating Results

May 4, 2026, 7:00 AM EDT - 9 days ago

Krystal Biotech Announces First Quarter 2026 Financial and Operating Results

Krystal Biotech to Present at Upcoming Scientific Conferences

Apr 30, 2026, 8:00 AM EDT - 13 days ago

Krystal Biotech to Present at Upcoming Scientific Conferences

Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026

Apr 21, 2026, 8:00 AM EDT - 22 days ago

Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026

Krystal Biotech initiated with a Peer Perform at Wolfe Research

2026-03-26T20:23:32.000Z - 6 weeks ago

Krystal Biotech initiated with a Peer Perform at Wolfe Research

Krystal Biotech price target raised to $325 from $318 at BofA

2026-03-24T11:35:21.000Z - 7 weeks ago

Krystal Biotech price target raised to $325 from $318 at BofA

Krystal Biotech Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 3:10 PM EST - 2 months ago

Krystal Biotech Transcript: TD Cowen 46th Annual Health Care Conference

Krystal Biotech price target raised to $284 from $224 at Guggenheim

2026-02-25T12:03:05.000Z - 2 months ago

Krystal Biotech price target raised to $284 from $224 at Guggenheim

Krystal Biotech price target raised to $323 from $220 at Chardan

2026-02-18T13:01:08.000Z - 2 months ago

Krystal Biotech price target raised to $323 from $220 at Chardan

Krystal Biotech price target raised to $371 from $336 at Citi

2026-02-18T11:11:02.000Z - 3 months ago

Krystal Biotech price target raised to $371 from $336 at Citi

Krystal Biotech price target raised to $371 from $310 at Jefferies

2026-02-17T18:35:39.000Z - 3 months ago

Krystal Biotech price target raised to $371 from $310 at Jefferies

Krystal Biotech Earnings Call Transcript: Q4 2025

Feb 17, 2026, 8:30 AM EST - 3 months ago

Krystal Biotech Earnings Call Transcript: Q4 2025

Krystal Biotech sees FY26 non-GAAP R&D, SG&A expense $175M-$195M

2026-02-17T12:11:57.000Z - 3 months ago

Krystal Biotech sees FY26 non-GAAP R&D, SG&A expense $175M-$195M

Krystal Biotech reports Q4 EPS $1.70, consensus $1.61

2026-02-17T12:05:09.000Z - 3 months ago

Krystal Biotech reports Q4 EPS $1.70, consensus $1.61

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

Feb 17, 2026, 7:00 AM EST - 3 months ago

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

Feb 10, 2026, 8:00 AM EST - 3 months ago

Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

Krystal Biotech granted RMAT designation for KB707 in NSCLC

2026-02-09T13:11:11.000Z - 3 months ago

Krystal Biotech granted RMAT designation for KB707 in NSCLC

Krystal Biotech price target raised to $327 from $206 at Goldman Sachs

2026-01-30T12:37:18.000Z - 3 months ago

Krystal Biotech price target raised to $327 from $206 at Goldman Sachs

Krystal Biotech price target raised to $338 from $288 at Clear Street

2026-01-26T11:05:06.000Z - 3 months ago

Krystal Biotech price target raised to $338 from $288 at Clear Street

Krystal Biotech price target raised to $318 from $288 at BofA

2026-01-22T12:15:45.000Z - 3 months ago

Krystal Biotech price target raised to $318 from $288 at BofA

These under-the-radar stocks combine fast growth with big upside potential

Jan 15, 2026, 10:31 AM EST - 4 months ago

These under-the-radar stocks combine fast growth with big upside potential

AGYS ASTH BBT CORT CTRE DCOM DOCN

Krystal Biotech Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 10:30 AM EST - 4 months ago

Krystal Biotech Transcript: 44th Annual J.P. Morgan Healthcare Conference

Krystal Biotech price target raised to $336 from $320 at Citi

2026-01-12T11:45:45.000Z - 4 months ago

Krystal Biotech price target raised to $336 from $320 at Citi

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 1:00 PM EST - 4 months ago

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Krystal Biotech price target raised to $306 from $202 at TD Cowen

2026-01-09T13:05:41.000Z - 4 months ago

Krystal Biotech price target raised to $306 from $202 at TD Cowen

Krystal Biotech price target raised to $306 from $202 at TD Cowen

2026-01-09T13:00:57.000Z - 4 months ago

Krystal Biotech price target raised to $306 from $202 at TD Cowen

Krystal Biotech Transcript: Study Update

Jan 8, 2026, 4:30 PM EST - 4 months ago

Krystal Biotech Transcript: Study Update

Krystal Biotech Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 10:00 AM EST - 5 months ago

Krystal Biotech Transcript: Evercore ISI 8th Annual HealthCONx Conference

Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference

Nov 26, 2025, 8:00 AM EST - 5 months ago

Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference

Krystal Biotech Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:30 AM EST - 6 months ago

Krystal Biotech Earnings Call Transcript: Q3 2025

Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label

Sep 15, 2025, 8:00 AM EDT - 8 months ago

Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label

Krystal Biotech Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 10:20 AM EDT - 8 months ago

Krystal Biotech Transcript: Cantor Global Healthcare Conference 2025

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

Aug 21, 2025, 12:11 PM EDT - 9 months ago

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

Krystal Biotech Earnings Call Transcript: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 10 months ago

Krystal Biotech Earnings Call Transcript: Q2 2025

Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

Jul 25, 2025, 9:00 AM EDT - 10 months ago

Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech Transcript: Study Result

Jul 24, 2025, 4:30 PM EDT - 10 months ago

Krystal Biotech Transcript: Study Result

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

Jul 24, 2025, 8:00 AM EDT - 10 months ago

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

Krystal Biotech Transcript: Study Update

Jul 9, 2025, 8:30 AM EDT - 11 months ago

Krystal Biotech Transcript: Study Update

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis

Jul 9, 2025, 7:00 AM EDT - 11 months ago

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa

Jun 24, 2025, 7:00 AM EDT - 11 months ago

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa

Krystal Biotech Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 10, 2025, 2:00 PM EDT - 1 year ago

Krystal Biotech Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Krystal Biotech Transcript: BofA Securities 2025 Healthcare Conference

May 14, 2025, 2:20 PM EDT - 1 year ago

Krystal Biotech Transcript: BofA Securities 2025 Healthcare Conference

Krystal Biotech to Present at BofA Securities 2025 Health Care Conference

May 7, 2025, 8:00 AM EDT - 1 year ago

Krystal Biotech to Present at BofA Securities 2025 Health Care Conference

Krystal Biotech Earnings Call Transcript: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Krystal Biotech Earnings Call Transcript: Q1 2025

Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Apr 28, 2025, 7:00 AM EDT - 1 year ago

Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

Apr 7, 2025, 4:30 PM EDT - 1 year ago

Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

Krystal Biotech Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 1:50 PM EST - 1 year ago

Krystal Biotech Transcript: TD Cowen 45th Annual Healthcare Conference

Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Feb 28, 2025, 7:40 AM EST - 1 year ago

Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech Earnings Call Transcript: Q4 2024

Feb 19, 2025, 8:30 AM EST - 1 year ago

Krystal Biotech Earnings Call Transcript: Q4 2024

Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results

Feb 19, 2025, 7:00 AM EST - 1 year ago

Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

Feb 18, 2025, 10:20 AM EST - 1 year ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

ARWR AUB CRK CYTK EXE MARA MP

Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

Jan 14, 2025, 8:00 AM EST - 1 year ago

Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

Dec 18, 2024, 8:00 AM EST - 1 year ago

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

Krystal Biotech Transcript: Status Update

Dec 12, 2024, 8:30 AM EST - 1 year ago

Krystal Biotech Transcript: Status Update

Krystal Biotech Provides Update on EMA's Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa

Dec 9, 2024, 4:15 PM EST - 1 year ago

Krystal Biotech Provides Update on EMA's Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa

Krystal Biotech Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 4, 2024, 2:10 PM EST - 1 year ago

Krystal Biotech Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Krystal Biotech Transcript: Citi's 2024 Global Healthcare Conference

Dec 3, 2024, 8:45 AM EST - 1 year ago

Krystal Biotech Transcript: Citi's 2024 Global Healthcare Conference

Krystal Biotech to Present at Upcoming Investor Conferences

Nov 27, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech to Present at Upcoming Investor Conferences

Krystal Biotech Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 10:55 AM EST - 1 year ago

Krystal Biotech Transcript: Stifel 2024 Healthcare Conference

Krystal Biotech Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 12, 2024, 1:30 PM EST - 1 year ago

Krystal Biotech Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference

Nov 6, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference

Krystal Biotech Earnings Call Transcript: Q3 2024

Nov 4, 2024, 8:30 AM EST - 1 year ago

Krystal Biotech Earnings Call Transcript: Q3 2024

Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024

Oct 28, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024

Krystal Biotech Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 18, 2024, 1:20 PM EDT - 1 year ago

Krystal Biotech Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference

Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Krystal Biotech Transcript: Study Result

Aug 28, 2024, 4:30 PM EDT - 1 year ago

Krystal Biotech Transcript: Study Result

Krystal Biotech Earnings Call Transcript: Q2 2024

Aug 5, 2024, 8:30 AM EDT - 1 year ago

Krystal Biotech Earnings Call Transcript: Q2 2024

Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024

Jul 26, 2024, 8:00 AM EDT - 1 year ago

Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024

Krystal Biotech Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 11, 2024, 10:40 AM EDT - 2 years ago

Krystal Biotech Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Krystal Biotech to Present at the American Thoracic Society 2024 International Conference

May 15, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech to Present at the American Thoracic Society 2024 International Conference

Krystal Biotech Transcript: BofA Securities 2024 Health Care Conference

May 14, 2024, 5:20 PM EDT - 2 years ago

Krystal Biotech Transcript: BofA Securities 2024 Health Care Conference

Krystal Biotech to Present at BofA Securities 2024 Health Care Conference

May 8, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech to Present at BofA Securities 2024 Health Care Conference

Krystal Biotech Earnings Call Transcript: Q1 2024

May 6, 2024, 8:30 AM EDT - 2 years ago

Krystal Biotech Earnings Call Transcript: Q1 2024

Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates

May 6, 2024, 8:00 AM EDT - 2 years ago

Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates

Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

May 2, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024

Apr 26, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

Apr 22, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

Apr 4, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference

Feb 28, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference

Krystal Biotech Earnings Call Transcript: Q4 2023

Feb 26, 2024, 8:30 AM EST - 2 years ago

Krystal Biotech Earnings Call Transcript: Q4 2023

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Feb 26, 2024, 8:00 AM EST - 2 years ago

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

Feb 20, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung

Feb 13, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung

Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa

Feb 8, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa

Krystal Biotech Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Feb 7, 2024, 10:00 AM EST - 2 years ago

Krystal Biotech Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference

Feb 1, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference

Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®

Jan 4, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®

Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)

Dec 19, 2023, 7:00 AM EST - 2 years ago

Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa

Nov 27, 2023, 7:00 AM EST - 2 years ago

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech Transcript: The Stifel 2023 Annual Healthcare Conference

Nov 15, 2023, 11:30 AM EST - 2 years ago

Krystal Biotech Transcript: The Stifel 2023 Annual Healthcare Conference

Krystal Biotech to Present at the Stifel 2023 Healthcare Conference

Nov 9, 2023, 7:00 AM EST - 2 years ago

Krystal Biotech to Present at the Stifel 2023 Healthcare Conference

Krystal Biotech Earnings Call Transcript: Q3 2023

Nov 6, 2023, 8:30 AM EST - 2 years ago

Krystal Biotech Earnings Call Transcript: Q3 2023

Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update

Nov 6, 2023, 7:00 AM EST - 2 years ago

Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update

Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023

Oct 30, 2023, 7:00 AM EDT - 2 years ago

Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023

Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference

Sep 28, 2023, 7:00 AM EDT - 2 years ago

Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference

CapitalMonk
CapitalMonk May. 13 at 4:25 AM
$KRYS Price: $310.31 (-0.82%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±1.00% RSI: 70.1 | Momentum: Strong Momentum Volume: +3.1% vs avg Volatility: 2.58% Support: $251.97 | Resistance: $315.17 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
MorganHoratio
MorganHoratio May. 11 at 9:32 PM
Today, all of these stocks hit all-time highs at some point. Arrow Electronics $ARW Powell Industries $POWL Synnex $SNX Krystal Biotech $KRYS Enersys $ENS Today’s ATH list is a perfect showcase of a "Multi-Sector Breakout" across AI infra, Life Sciences, and Supply Chain! 🚀 As of May 11, 2026, $POWL hitting $328 reaffirms its dominance in power distribution. $ARW crossing $202 and $ENS breaking $236 highlight the massive recovery in AI hardware distribution and energy storage. Notably, $KRYS tapping $315 marks a pivotal re-rating for the biotech sector. The takeaway: 2026’s wealth effect is flowing beyond GPUs into "Power, Distribution, and Deep-Tech Bio." Which of these "non-GPU" leaders do you think has the most room to run? Let’s discuss your 2026 strategy below!
0 · Reply
ZManicItalian
ZManicItalian May. 11 at 2:02 PM
$KRYS 🍻🐂
0 · Reply
Doozio
Doozio May. 9 at 12:57 AM
$KRYS ONTO 🐒🍌🧠⏰♾️
0 · Reply
trichomy
trichomy May. 7 at 1:43 PM
$INMB $INMB $KRYS $MESO $NVAX $MRNA There is NO reason why InmuneBio is less than $ 3 right now It is trading at 1.5 right now . Fire sale!!
0 · Reply
trichomy
trichomy May. 6 at 4:40 PM
$INMB $INMB $ABEO $KRYS $MESO $IBRX We are in the eye of the storm . Volume already way up. This is the calm before tomorrow Booyah! Wake up people! 🔥 🔥 INMB 🔥 🔥
2 · Reply
Synaptric
Synaptric May. 6 at 1:35 PM
Narrow-tech-only-market angst? Check out 52-week highs in Healthcare $ARWR $CYTK $JAZZ $BTSG $KRYS
0 · Reply
trichomy
trichomy May. 5 at 9:38 PM
$INMB $INMB expands collab with Anthony Nolan charity for umbilical cord tissue supply to advance CORDStrom hucMSC platform — targeting RDEB (CORDStrom-col7a), solid tumors (TRAIL), OA & more. Prepping for commercial approval! Strong supply deal + regulatory momentum in hot cell/gene therapy & rare disease space. $ABEO $KRYS $MESO $IBRX #biotech #celltherapy #RDEB https://www.stocktitan.net/news/INMB/i-nmune-bio-and-anthony-nolan-announce-strategic-expansion-of-cord-r715r3sueyi2.html
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 5 at 2:26 PM
$KRYS RSI: 65.22, MACD: 4.7468 Vol: 8.86, MA20: 270.13, MA50: 262.71 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
VAK7
VAK7 May. 5 at 3:36 AM
$HOOD $KRYS $NBIS $RCUS $TGTX That was a very nice summary. And picks. And set me up for 75% 1 yeah performance since 5/4/25. TGTX and HOOD are lagging from this cohort of 5. But not for long. Imho TGTX will be over $45 this year; and HOOD will be in triple digits, no doubt about it. I could have done better, but, to my defense, MW should have sold TGTX before summer 2025; I told myself that if he does not do that, or buy out EU rights, i will reduce my TGTX position before 2 year term to buyback EU rights lapses. And I did not. Price you pay for your own indecisiveness.
0 · Reply
1986iamwallstreet
1986iamwallstreet May. 4 at 1:49 PM
$KRYS dips bought about to take off
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 4 at 11:11 AM
$KRYS Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $1.91 up 54.03% YoY • Reported revenue of $116.36M up 31.95% YoY
0 · Reply
1986iamwallstreet
1986iamwallstreet May. 4 at 11:04 AM
$KRYS Krystal Biotech Q1 EPS $1.83 Beats $1.39 Estimate, Sales $116.357M Beat $112.132M Estimate
0 · Reply
1986iamwallstreet
1986iamwallstreet May. 1 at 2:10 PM
$KRYS another one that can get bought out
0 · Reply
SuperGreenToday
SuperGreenToday May. 1 at 3:31 AM
$KRYS Share Price: $261.97 Contract Selected: Nov 20, 2026 $260 Calls Buy Zone: $32.73 – $40.43 Target Zone: $52.76 – $64.49 Potential Upside: 52% ROI Time to Expiration: 203 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BillionerOfKing
BillionerOfKing Apr. 29 at 8:40 PM
$KRYS Current Stock Price: $259.64 Contracts to trade: $260.0 KRYS May 15 2026 Call Entry: $12.00 Exit: $21.44 ROI: 79% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
IN0V8
IN0V8 Apr. 20 at 7:27 PM
$KRYS Buy Jefferies raises target price to $380 from $371
0 · Reply
GECE
GECE Apr. 15 at 6:50 AM
$KRYS damn. Should have hold this one when I bought at 30 and sold at 60…
0 · Reply
1GreenDay99RedDays
1GreenDay99RedDays Mar. 2 at 8:43 PM
$KRYS been a monster for 5 years i comment and blamo
0 · Reply
GorillaTrades
GorillaTrades Feb. 27 at 8:22 PM
Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: Cboe Global Markets $CBOE +4.7%, Krystal Biotechnology $KRYS +4.7%, and Agree Realty $ADC +3.5%
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 10:34 PM
$KRYS RSI: 52.04, MACD: 1.0698 Vol: 6.74, MA20: 273.76, MA50: 265.48 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply